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Abstract—Diabetes predisposes to aortic stenosis (AS). We aimed to investigate if diabetes affects
the expression of selected coagulation proteins and inﬂammatory markers in AS valves. Twenty
patients with severe AS and concomitant type 2 diabetes mellitus (DM) and 40 well-matched
patients without DM scheduled for valve replacement were recruited. Valvular tissue factor (TF),
TF pathway inhibitor (TFPI), prothrombin, C-reactive protein (CRP) expression were evaluated by
immunostaining and TF, prothrombin, and CRP transcripts were analyzed by real-time PCR.
DM patients had elevated plasma CRP (9.2 [0.74–51.9] mg/l vs. 4.7 [0.59–23.14] mg/l, p=0.009) and
TF (293.06 [192.32–386.12] pg/ml vs. 140 [104.17–177.76] pg/ml, p=0.003) compared to non-DM
patients. In DM group, TF−, TFPI−, and prothrombin expression within valves was not related to
demographics, body mass index, and concomitant diseases, whereas increased expression related to
DM was found for CRP on both protein (2.87 [0.5–9]% vs. 0.94 [0–4]%, p=0.01) and transcript levels
(1.3±0.61 vs. 0.22±0.43, p=0.009). CRP-positive areas were positively correlated with mRNA
TF (r=0.84, p=0.036). Diabetes mellitus is associated with enhanced inﬂammation within AS
valves, measured by CRP expression, which may contribute to faster AS progression.
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INTRODUCTION
Aortic stenosis (AS) is the most frequent heart
valve disease and the most common cause of heart valve
replacement in the elderly [1]. It is characterized by
massive ﬁbrous thickening of valve leaﬂets and
extensive focal calciﬁcation [2]. The development and
progression of AS is an active inﬂammatory process,
including disruption of the basement membrane,
subendothelial accumulation of intracellular lipids,
lipoproteins and molecular mediators of calciﬁcation,
together with inﬁltration of the inﬂammatory cells and
activation of local and systemic inﬂammation [3, 4].
The concept of AS as an atherosclerosis-like process
is supported by a number of studies showing that
development of AS is associated with cardiovascular
risk factors such as smoking, hypercholesterolemia,
and arterial hypertension [5, 6]. Diabetes mellitus
(DM) has also been reported to represent a risk factor
for AS however little is known about this association
despite the strong impact of DM on coronary athero-
sclerosis [7]. Diabetes accompanied by inﬂammation
is thought to play an important role in enhancing the
pathophysiological mechanism of atherosclerosis [8].
It appears that CRP is directly involved in pro-atherogenic
changes by ampliﬁcation of vascular inﬂammatory
response through complement activation, endothelial
cell activation, and ﬁnally tissue damage [9]. Peripheral
monocytes inﬁltrate early atherosclerotic lesions and
show a high activation state in diabetes [10]. The pro-
inﬂammatory state of diabetic monocytes is characterized
by increased intranuclear factor kappa B (NFκB),
regulating pro-inﬂammatory genes [11] and induces an
intravascular oxidative stress response [12], leading to
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TF expression [13]. TF was found to be an independent
factor related to microvascular diabetic complications and
it reﬂects endothelial dysfunction and procoagulant
activity [14]. Recently, it has been shown that DM is
associated with coronary artery calcium scores [15],
aortic valve calciﬁcation [7] assessed by electron-
beam computed tomography, and with faster AS
progression [16]. It has been proposed that enhanced
inﬂammation is implicated in progression of both DM
[17] and AS [18]. Recent observations made in human
aortic valves from patients with AS demonstrated
increased expression of CRP and showed that the
amount of pro-inﬂammatory proteins increased with
the progression of AS [19]. Increased expression of tissue
factor (TF), a major initiator of blood coagulation in vivo,
associated with macrophage inﬁltration and neovascu-
larization has been also demonstrated within the
stenotic valves [20, 21].
To our knowledge, there have been no reports
showing if DM affects the valvular expression of
inﬂammatory and/or coagulation proteins in AS patients.
Therefore, we sought to investigate whether DM
inﬂuences the expression of CRP as well as TF, its
inhibitor—TFPI (TF pathway inhibitor) and prothrombin
in a representative patient population with advanced AS
without clinically overt atherosclerotic vascular disease.
MATERIALS AND METHODS
Patients
A total of 60 consecutive patients (27 men and 33
women) undergoing isolated elective aortic valve
replacement for severe AS (mean transvalvular
gradient ≥40 mmHg) were recruited. The exclusion
criteria were: acute infection, Valsalva sinus aneurysm
or rheumatic AS, angiographically documented epicardial
artery stenosis >20% diameter, known cancer, auto-
immune disorders, endocarditis, previous cardiac surgery,
a history of myocardial infarction, stroke, venous
thromboembolism, or bleeding. Patients who required
additional surgical intervention or had other heart
defects were ineligible.
Information on the presence or absence of cardio-
vascular risk factors, including arterial hypertension,
hyperlipidemia, DM, and use of statins, angiotensin-
converting enzyme inhibitors, β blockers and acetylsa-
licylic acid was obtained before surgery. Patients were
classiﬁed as having DM (n=20) if they were receiving
insulin (n=7, 35%), oral hypoglycemic agents (n=13,
65%), and/or had fasting glucose levels >7 mmol/l.
Only patients with DM without renal dysfunction
(based on having at least two random fasting creatinine
levels of >110 μmol/l for male and >80 μmol/l for female)
were enrolled. Arterial hypertension was diagnosed based
on a history of hypertension (blood pressure >140/
90 mmHg) or preadmission antihypertensive treatment.
Patients gave their informed consent and the study was
approved by the University Bioethical Committee. Five
aortic valves from age-matched apparently healthy
subjects, obtained at autopsy, without morphological
valvular or other cardiac disorders served as negative
controls.
All measurements and tissue analysis were
performed by technicians blinded to the origin of the
samples. The samples were uncoded during statistical
analysis.
Echocardiography
Transthoracic echocardiography was performed in
each patient using a GE Vivid 7 ultrasound machine
prior to surgery using conventional techniques in
accordance with the European Society of Cardiology
guidelines. The aortic valve area (AVA) was calculated
using the standard continuity equation [22]. The
transvalvular gradient was measured by Doppler
echocardiography using the modiﬁed Bernoulli equation
[22].
Laboratory Tests
Fasting venous blood was drawn from patients
within 24 h before surgery between 5AM and 9AM.
Citrated blood samples (9:1 of 0.129 M citrate) were
centrifuged at 3,000 rpm at 20°C for 10 min and stored
in aliquots at −80°C until analysis. Glucose and
creatinine were assayed by routine laboratory techniques.
High-sensitivity C-reactive protein (CRP) was determined
using immunoturbidimetry (Siemens Healthcare Diag-
nostics, Deerﬁeld, IL, USA). Commercially available
ELISA test was used to determine in citrated plasma
TF (American Diagnostica Inc., Stamford, CT, USA)
according to manufacturer's instructions. Intra-assay
and inter-assay coefﬁcients of variation were <8%.
Analysis of Aortic Valves
Diseased aortic valves were collected during
surgery for valve replacement. Cryopreserved valves
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were cryosectioned on 10-μm thick sections, as
described before [20]. Slides were stored at −20°C
until immunostaining. Immunohistochemistry was
performed on adjacent sections of aortic valves as
described before [20]. Brieﬂy, after endogenous
peroxidase activity quenching and blocking of unspe-
ciﬁc background, primary monoclonal antibodies
were applied overnight at 4°C against human TF
(R&D Systems, Inc., Minneapolis, USA), TFPI
(American Diagnostica Inc., Stamford, CT, USA),
prothrombin (HyphenBioMed, Neuville-Sur-Oise,
France) or CRP (Santa Cruz Biotechnology, Inc.,
CA, USA). Primary antibodies were followed by the
corresponding secondary antibodies and by the
avidin-biotin complex immunoperoxidase according
to manufacturer's instructions (Santa Cruz Biotech-
nology Inc., CA, USA) and visualized using the
diamninobenzidine. A negative control (without primary
antibody incubation) was included routinely. Sections
were viewed in light microscope (Zeiss, Berlin, Germany).
Photomicrographs were taken using a Canon A640
camera and analyzed using the image analysis software
cellAnalyst. The extent of immunoreactive areas of
analyzed antigens was quantiﬁed in nine serial-step
sections per valve as described by Lamprecht et al. [23].
Nucleic Acid Extraction
Human valves obtained during aortic valve
replacement were immediately placed in RNALater
(Qiagen, Chatsworth, CA, USA) and stored in liquid
nitrogen. Frozen valve cups were pulverized using
Mikro-Dismembrator S (Sartorius Stedim Biotech,
Germany). Total RNA was isolated with the RNeasy
Mini kit, according to the manufacturer's recommended
protocols (Qiagen, Chatsworth, CA, USA) and digested
with DNase (DNase I recombinant, RNase-Free, Qiagen,
Chatsworth, CA, USA) following the manufacturer's
instructions. The RNA concentration was estimated by
A260 measurement, and the samples were stored at −80°C.
Quantiﬁcation of TF, Prothrombin, IL-6, and CRP
Transcripts by Real-time PCR
A total of 1 μg of RNA from each individual valve
cups was reverse-transcribed to single-strain cDNA
using High Capacity RNA-to-cDNA Master Mix
(Applied Biosystems) at 25°C for 5 min, 42°C for
30 min followed by 85°C for 5 min. The cDNA was
ampliﬁed with TaqMan Gene Expression Assays
containing both primers and probe (TF, assay ID
Hs01076032_m1; prothrombin, Hs00354679_m1; IL-6,
Hs00985639_m1; and CRP, Hs00265044_m1) on an ABI
PRISM® 7900HT Fast Real-Time PCR System (Applied
Biosystems). The assays were fromApplied Biosystems as
inventoried or made-to-order.
Beta-actin (Hs99999903_m1, human ACTB
Endogenous Control FAM/MGB Probe, Non-Primer
Limited; Applied Biosystems) was used as a house-
keeping gene. To analyze the obtained data, the com-
parative threshold cycle (CT) method was applied [24].
Brieﬂy, the amount of a target gen, normalized to
ACTB, and relative to a calibrator (normal valve leaﬂet),
is given by 2−ΔΔCT, where ΔΔCT=ΔCT of a sample (the
CT of the target gene of AS valves subtracted from the
CT of ACTB)—ΔCT of calibrator.
Statistical Analysis
Values are expressed as mean (SD) or median
(interquartile range) or otherwise stated. The Kolmogorov–
Smirnov test was used to assess conformity with a normal
distribution. Pairwise comparisons were made using the
Tukey's test for continuous variables and the χ2 test for
proportions. The Mann–Whitney U test was used to
compare non-normally distributed variables between two
groups. The Spearman's correlation coefﬁcient was
calculated to evaluate associations between variables. A
value of p<0.05 was considered statistically signiﬁcant.
RESULTS
Baseline characteristics of patients from DM and
non-DM groups are shown in Table 1.
Patients with DM had elevated plasma CRP (9.2
[0.74–51.9] mg/l vs. 4.7 [0.59–23.14] mg/l, p=0.009) and
TF (293.06 [192.32–386.12] pg/ml vs. 140 [104.17–177.76]
pg/ml, p=0.003) levels compared to non-DM patients.
Immunohistochemistry and Immunoﬂuorescence
Focal areas of subendothelial thickening were seen
in the AS valves from both DM and non-DM groups.
Immunohistochemical staining of aortic valve tissue
showed the abundance of TF antigen at the aortic side
of the leaﬂets, colocalizing with TFPI-positive areas
in both DM and non-DM groups; however, there
were no statistically signiﬁcant differences in TF or
TFPI expression within valves from DM vs. non-DM
group (20.43±10.44% vs. 17.46±9.44%, p=0.56; and
46.17±12.61% vs. 39.53±10.4%, p=0.63, respectively).
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Prothrombin antigen was detected in both groups and
the expression of this antigen did not differ between
DM and non-DM valves (26.05±12.47% vs. 23.42±
13%, p=0.72). Of note, prothrombin was colocalized
with TF and TFPI; however, areas positive for
prothrombin were also visible in other TF-free
regions. CRP expression within stenotic valves was
detected in ﬁbrosa but not in valvular spongiosa
(Fig. 1). Compared to non-DM, valves from DM
group were characterized by increased expression of
CRP (0.94[0–4]% vs. 2.87[0.5–9]%, p=0.01), (Fig. 2a).
There was no age-, gender-, or smoking-related
differences in the percentage of areas positive for TF,
TFPI, prothrombin-, or CPR antigens. There was a
positive correlation between TF- and TFPI-positive areas
in both DM and non-DM groups (r=0.77, p=0.002; r=
0.74, p<0.0001, respectively) and between TF and
prothrombin (r=0.76, p=0.004; r=0.51, p=0.003,
respectively). Interestingly, CRP expression within
valves was positively correlated with TF expression in
DM but not in non-DM group (r=0.83, p=0.0001; r=
0.19, p=0.063, respectively). In both DM and non-DM
groups, there were positive correlations of TF with
maximal (r=0.7, p=0.005; r=0.5, p=0.008, respec-
tively) and mean (r=0.58, p=0.03; r=0.71, p=0.004,
respectively) gradients and inverse correlation of AVA
(r=−0.67, p=0.004; r=−0.93, p=0.001, respectively),
but not with LVEF (r=0.2, p=0.094; r=0.14, p=0.45).
Positive correlations of prothrombin with maximal
(r=0.54, p=0.02; r=0.85, p=0.004) and mean (r=
0.62, p=0.03; r=0.87, p=0.003) gradients and
inverse correlation with AVA (r=−0.42, p=0.04; r=−0.88,
p=0.004) were also found. No signiﬁcant correlations were
found between analyzed protein expressions and plasma
levels of CRP and TF.
Valvular mRNA Expression
Analysis of relative gene expression data using
real-time quantitative PCR has shown increased
expression of CRP (1.3±0.61 vs. 0.22±0.43, p=0.009)
but not TF (2.6±0.83 vs. 1.7±0.16, p=0.39) or prothrom-
bin (0.31±1.33 vs. 0.27±0.04, p=0.8) in DM group
compared to non-DM group (Fig. 2b). Moreover, positive
Table 1. Baseline Characteristics of Patients with (DM) and without (non-DM) Diabetes Mellitus
DM (n=20) non-DM (n=40) P value
Male, n (%) 11 (55) 16 (40) 0.2
Age, years 66.42±7.7 62.23±11.06 0.44
Body mass index (kg/m2) 31.08±5.3 29.6±5.51 0.18
Echocardiography
Mean aortic gradient (mmHg) 61.87±25.26 55.12±22.29 0.36
Maximum aortic gradient (mmHg) 86.9±24.6 93.01±24.7 0.11
LVEF (%) 53.13±16.39 57.44±12.58 0.33
AVA (cm2) 0.73±0.19 0.72±0.23 0.93
Treatment
Beta blockers, n (%) 11 (55) 20 (50) 0.61
Acetylsalicylic acid, n (%) 13 (65) 23 (57) 0.77
Statins, n (%) 10 (50) 16 (40) 0.28
ACEIs, n (%) 6 (30) 21 (52) 0.01
Data are given as mean±SD, median (IQR) or number (percentage)
LVEF left ventricular ejection fraction, AVA aortic valve area, ACEIs angiotensin-converting enzyme inhibitors
Fig. 1. Photomicrograph of representative valve lesion showing
immunodetection of C-reactive protein within stenotic aortic valves in
patients with diabetes mellitus. Immunopositive areas are stained brown.
Asterisk shows aortic side of the leaﬂet.
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correlations of mRNA for TF with areas immunopositive
for CRP were found in DM patients (r=0.84, p=0.036).
No signiﬁcant correlations were found between
analyzed mRNA expressions and plasma levels of CRP
and TF.
DISCUSSION
To our knowledge, the current study is the ﬁrst to
show that in subjects with AS, DM augments the
expression of crucial pro-inﬂammatory protein—CRP
within aortic valves. Our major ﬁndings can be
summarized as follows: (1) DM is associated with an
increased percentage of CRP-positive areas within
stenotic valves, which is correlated with areas positive
for TF, and (2) mRNA for TF is positively correlated
with the percentage of CRP-immunopositive areas in
patients with DM.
Disputing the classic dogma that CRP is synthesized
exclusively by the liver in response to inﬂammatory
cytokines, recent reports have shown that CRP is
produced in various non-hepatic tissue and cells. Of
major relevance, CRP expression has been detected in
the arterial tissue and increased levels of CRP mRNA
have been documented in atherosclerotic plaque [25].
Consisting with these ﬁndings, stimulatory effect of
oxidized low-density lipoproteins on CRP synthesis
Fig. 2. Quantitative analysis of a immunostained C-reactive protein (CRP), tissue factor (TF), tissue factor pathway inhibitor (TFPI) and prothrombin,
and b mRNA levels of CRP, TF, and prothrombin, within aortic valves in patients with aortic stenosis and with (DM) or without (non-DM) diabetes
mellitus. Bars represent means±SD or median (IQR). A p value <0.05 was considered statistically different.
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by freshly isolated human monocytes has been also
shown [26].
It has been proposed that inﬂammation plays a
crucial intermediatory role in the pathogenesis of
glucose disorders in adults [27, 28], thereby linking
diabetes with a number of commonly coexisting
conditions thought to originate through inﬂammatory
mechanisms, such as CRP. In this study, elevated
plasma CRP level was associated with the develop-
ment of diabetes, supporting the previous data [17,
29] and expanding our previous data, showing
stenosed valves inﬂammation manifested by huge
macrophage inﬁltrations [20] and emphasizing the
role of local inﬂammation within stenosed valves. An
independent association of CRP with AS progression has
been also previously documented by Galante et al. [30]
arising a new understanding of the physiological role
of CRP in stenotic valves, through promoting local
proinﬂammatory effects. The reported immunoregulatory
functions of CRP include enhancement of macrophages
and T lymphocytes activity with subsequent tissue
damage, complement ﬁxation, and modulation of
platelet activation [31, 32], which leads to valve cusp
degradation and AS progression. Our previous study
has shown that macrophage inﬁltrations is colocalized
with large amounts of TF within stenosed valves [20],
which suggests that macrophages play a vital role in
TF synthesis and are important in a cross-talk between
inﬂammatory and coagulatory processes in this disease.
In other studies, we have shown that within the
stenotic valves, the TF molecules are active and lead
to thrombin formation [33]. Giving the data that
thrombin has been shown to enhance valve calciﬁca-
tion and AS progression [21], it might be suggested
that faster AS progression in DM patients is an effect
of enhancing inﬂammatory and coagulation processes
within valve cusps, which leads to increased valve
leaﬂets calciﬁcation.
Study Limitations
First, the number of DMpatients enrolled in this study
was limited. However, both groups were well matched.
Additionally, the severity, and the duration of DMwere not
the same in patients from DM group. Second, the present
study is focused on the valves obtained from patients with
severe AS. Once the valve is heavily calciﬁed, inﬂamma-
tion may play less of a role in progression of AS than in a
valve with less severe disease and the inﬂuence of DM on
AS may be masked to some extent. Therefore, our results
cannot be evaluated using the current approach and
extrapolated on subjects with mild AS. Third, patients
from DM group had BMI>30 kg/m2, and obesity-
mediated CRP production is an important mechanism for
systemic elevation of this protein [29], which could
partially inﬂuence the results. Finally, glycated
hemoglobin, a retrospective DM indicator, has not been
measured which could be the reason of the lower detection
of DM [34].
In conclusion, diabetes was found to be associated
with increased inﬂammation within AS valves, as
measured by CRP expression. Further studies are
warranted to determine whether screening for aortic
valve disease should be recommended in patients with
diabetes mellitus. Also, further investigations are needed
to deﬁne whether interventions that directly target
insulin resistance in diabetes might retard or reverse
the progression of AS.
ACKNOWLEDGMENTS
This study has been supported by a grant of Polish
Ministry of Science (# N N402 383338, to A.U.).
Conﬂict of interest. None.
Open Access. This article is distributed under the terms
of the Creative Commons Attribution Noncommercial
License which permits any noncommercial use,
distribution, and reproduction in any medium, provided
the original author(s) and source are credited.
REFERENCES
1. Otto, C.M., B.K. Lind, D.W. Kitzman, B.J. Gersh, and D.S.
Sisovick. 1999. Associations of aortic valve sclerosis with
cardiovascular mortality and morbidity in the elderly. The New
England Journal of Medicine 341: 142–147.
2. Ortlepp, J.R., M. Pillich, F. Schmitz, V. Mevissen, R. Koos, S.
Weiss, L. Stork, R. Dronskowski, G. Langebartels, R. Autschbach,
V. Brandenburg, S. Woodruff, J.J. Kaden, and R. Hoffmann. 2006.
Lower serum calcium levels are associated with greater calcium
hydroxyapatite deposition in native aortic valves of male patients
with severe calciﬁc aortic stenosis. The Journal of Heart Valve
Disease 15: 502–508.
3. Yetkin, E., and J. Waltenberger. 2009. Molecular and cellular
mechanisms of aortic stenosis. International Journal of Cardiology
135: 4–13.
839Diabetes Modulates Aortic Stenosis by Inﬂammation Augmentation
4. Mohty, D., P. Pibarot, J.P. Després, C. Côté, B. Arsenault, A.
Cartier, P. Cosnay, C. Couture, and P. Mathieu. 2008. Association
between plasma LDL particle size, valvular accumulation of
oxidized LDL, and inﬂammation in patients with aortic stenosis.
Arteriosclerosis, Thrombosis, and Vascular Biology 28: 187–193.
5. Pate, G.E. 2002. Association between aortic stenosis and
hypertension. The Journal of Heart Valve Disease 11: 612–614.
6. Ngo, M.V., J.S. Gottdiener, R.D. Fletcher, D.J. Fernicola, and B.J.
Gersh. 2001. Smoking and obesity are associated with progression
of aortic stenosis. The American Journal of Geriatric Cardiology
10: 86–90.
7. Katz, R., N.D. Wong, R. Kronmal, J. Takasu, D.M. Shavelle, J.L.
Probstﬁeld, A.G. Bertoni, M.J. Budoff, and K.D. O'Brien. 2006.
Features of the metabolic syndrome and diabetes mellitus as
predictors of aortic valve calciﬁcation in the Multi-Ethnic Study of
Atherosclerosis. Circulation 113: 2113–2119.
8. Jawień, J. 2008. New insights into immunological aspects of
atherosclerosis. Polskie Archiwum Medycyny Wewnętrznej 118:
127–131.
9. Miłosz, D., L. Czupryniak, M. Saryusz-Wolska, G. Zasadzińska,
A. Borkowska, E. Cieplucha, K. Chizyński, and J. Loba. 2007.
Adiponectinemia, inﬂammatory process activity, and endothelial
dysfunction in patients with type 2 diabetes and acute coronary
syndrome with ST elevation in relation to the severity of lesions in
the coronary arteries. Polskie Archiwum Medycyny Wewnętrznej
117: 343–349.
10. Cipolletta, C., K.E. Ryan, E.V. Hanna, and E.R. Trimble. 2005.
Activation of peripheral blood CD14+ monocytes occurs in
diabetes. Diabetes 54: 2779–2786.
11. Voleti, B., and A. Agrawal. 2005. Regulation of basal and induced
expression of C-reactive protein through an overlapping element
for OCT-1 and NF-kappaB on the proximal promoter. Journal of
Immunology 175: 3386–3390.
12. Guerrero-Romero, F., and M. Rodríguez-Morán. 2006. Hypomag-
nesemia, oxidative stress, inﬂammation, and metabolic syndrome.
Diabetes/Metabolism Research and Reviews 22: 471–476.
13. Bierhaus, A., T. Illmer, M. Kasper, T. Luther, P. Quehenberger, H.
Tritschler, P. Wahl, R. Ziegler, M. Müller, and P.P. Nawroth. 1997.
Advanced glycation end products-mediated induction of tissue
factor in cultured endothelial cells is dependent on RAGE.
Circulation 96: 2262–2271.
14. Sommeijer, D.W., H.R. Hansen, R. van Oerle, K. Hamulyak, A.P.
van Zanten, E. Meesters, H.M. Spronk, and H. Cate. 2006. Soluble
tissue factor is a candidate marker for progression of microvascular
disease in patients with Type 2 diabetes. Journal of Thrombosis
and Haemostasis 4: 574–580.
15. Wolfe, M.L., N. Iqbal, W. Gefter, E.R. Mohler 3rd, D.J. Rader, and
M.P. Reilly. 2002. Coronary artery calciﬁcation at electron beam
computed tomography is increased in asymptomatic type 2
diabetics independent of traditional risk factors. Journal of
Cardiovascular Risk 9: 369–376.
16. Kamalesh, M., C. Ng, H. El Masry, G. Eckert, and S. Sawada.
2009. Does diabetes accelerate progression of calciﬁc aortic
stenosis? European Journal of Echocardiography 10: 723–725.
17. Pradhan, A.D., J.E. Manson, N. Rifai, J.E. Buring, and P.M.
Ridker. 2001. C-reactive protein, interleukin 6, and risk of
developing type 2 diabetes mellitus. JAMA 286: 327–334.
18. Sanchez, P.L., and A.M. Mazzone. 2006. C-reactive protein in
aortic valve disease. Cardiovascular Ultrasound 4: 37–40.
19. Toli, K., K.I. Paraskevas, M.V. Poulakou, G. Agrogiannis, N.
Kavantzas, V. Xanthopoulos, D.G. Iliopoulos, I. Mantas, A.
Papachristodoulou, E. Patsouris, D.P. Mikhailidis, and D.N. Perrea.
2008. Association between plasma levels and immunolocalization
of cytokines in heart valve lesions: a possible target for treatment?
Expert Opinion on Therapeutic Targets 12: 1209–1215.
20. Natorska, J., G. Marek, M. Hlawaty, D. Sobczyk, J. Sadowski, W.
Tracz, and A. Undas. 2009. Evidence for tissue factor expression in
aortic valves in patients with aortic stenosis. Polskie Archiwum
Medycyny Wewnętrznej 119: 636–642.
21. Breyne, J., F. Juthier, D. Croseaux, S. Marechaux, Ch Zawadzki, E.
Jeanpierre, A. Ung, P.V. Ennezat, S. Susen, E. Van Belle, H. Le
Marec, A. Vincentelli, T. Le Tourneau, and B. Jude. 2010.
Atherosclerotic-like process in aortic stenosis: Activation of
the tissue factor-thrombin pathway and potential role through
osteopontin alternation. Atherosclerosis 213: 369–376.
22. Teirstein, P., M. Yeager, P.G. Yock, and R.L. Popp. 1986. Doppler
echocardiographic measurement of aortic valve area in aortic
stenosis: a noninvasive application of the Gorlin formula. Journal
of the American College of Cardiology 8: 1059–1065.
23. Lamprecht, M.R., D.M. Sabatini, and A.E. Carpenter. 2007. Cell
proﬁler: Versalite software for automated biological image
analysis. BioTechniques 42: 71–75.
24. Clark-Greuel, J.N., J.M. Connolly, E. Sorichillo, N.R. Narula, H.E.
Rapoport, E.R. Mohler, J.H. Gorman, R.C. Gorman, and R.J. Levy.
2007. Transforming growth factor beta-1 mechanisms in aortic
valve calciﬁcation: Increased alkaline phosphatase and related
events. The Annals of Thoracic Surgery 7: 946–953.
25. Yasojima, K., C. Schwab, E.G. McGeer, and P.L. McGeer. 2001.
Generation of C-reactive protein and complement components in
atherosclerotic plaques. American Journal of Pathology 158:
1039–1051.
26. Mugabo, Y., L. Li, and G. Renier. 2010. The connection between
C-reactive protein (CRP) and diabetic vasculopathy. Focus on
preclinical ﬁndings. Current Diabetes Reviews 6: 27–34.
27. Barzilay, J.I., L. Abraham, S.R. Heckbert, M. Cushman, L.H.
Kuller, H.E. Resnick, and R.P. Tracy. 2011. The relation of
markers of inﬂammation to the development of glucose
disorders in the elderly: The Cardiovascular Health Study.
Diabetes 50: 2384–2389.
28. Sjöholm, A., and T. Nyström. 2006. Inﬂammation and the etiology of
type 2 diabetes.Diabetes/Metabolism Research and Reviews 22: 4–10.
29. Sweat, V., V. Starr, H. Bruehl, A. Arentoft, A. Tirsi, E. Javier, and
A. Convit. 2008. C-reactive protein is linked to lower cognitive
performance in overweight and obese women. Inﬂammation 31:
198–207.
30. Galante, A., A. Pietroiusti, M. Vellini, P. Piccolo, G. Possati, M. De
Bonis, R.L. Grillo, C. Fontana, and C. Favalli. 2001. C-reactive
protein is increased in patients with degenerative aortic valvular
stenosis. Journal of the American College of Cardiology 38:
1078–1082.
31. Kaden, J.J., C.E. Dempﬂe, R. Grobholz, C.S. Fischer, D.C. Vocke,
R. Kiliç, A. Sarikoç, R. Piñol, S. Hagl, S. Lang, M. Brueckmann,
and M. Borggrefe. 2005. Inﬂammatory regulation of extracellular
matrix remodeling in calciﬁc aortic valve stenosis. Cardiovascular
Pathology 14: 80–87.
32. Marnell, L., C. Mold, and T.W. Du Clos. 2005. C-reactive protein:
ligands, receptors and role in inﬂammation. Clinical Immunology
117: 104–111.
33. Natorska, J., G. Marek, M. Hlawaty, J. Sadowski, W. Tracz, and
A. Undas. 2011. Fibrin presence within aortic valves in
patients with aortic stenosis: Association with in vivo thrombin
generation and ﬁbrin clot properties. Thrombosis and Haemostasis
105: 254–260.
34. Drzewoski, J., and A. Drozdowska. 2010. Could glycated
hemoglobin be used as a diagnostic tool in diabetes mellitus?
Polskie Archiwum Medycyny Wewnętrznej 20: 109–114.
840 Natorska, Wypasek, Grudzień, Sobczyk, Marek, Filip, Sadowski, and Undas
